- Motley Fool•3 hours ago
Merck, Novartis, Novo Nordisk, Regeneron, and Sanofi await big FDA decisions in May.
- Motley Fool•yesterday
The FDA has approved Dupixent for moderate to severe eczema, and it has accepted the company's resubmission of sarilumab for rheumatoid arthritis. These drugs could give shares the shot in the arm they need.
- Zacks•2 days ago
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||46.90 - 47.52|
|52 Week Range||36.81 - 47.52|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.31|
|Dividend & Yield||1.58 (3.40%)|
|1y Target Est||N/A|